TLPH_OUT_1 [2025-04-01 08:20:01 -0400] 2174 Bytes | 619 tokens | Cum: 619 tkns (7.74% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 8:20:00 AM on Tue Apr 01, 2025 -0400, and I'm firing up the spotlight on Talphera (TLPH), moving from 0.495 to 0.5742. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

Here's the first list of news for Talphera:

C1 - Today 03:03AM - Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights
C2 - Mar-31-25 06:33PM - Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript
C3 - Mar-31-25 06:33PM 04:05PM - Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
C4 - Mar-31-25 06:33PM 08:30AM - Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million
C5 - Mar-26-25 04:38PM - Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025
C6 - Jan-14-25 08:30AM - Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study
C7 - Nov-24-24 07:27PM - Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
C8 - Nov-14-24 02:14AM - Talphera Inc (TLPH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Talphera (TLPH)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

TLPH_OUT_3 [2025-04-01 08:20:06 -0400] 1099 Bytes | 316 tokens | Cum: 937 tkns (11.71% of 8k)
==========================================================================

Showing C4 (chunk 1 of 14): C4:
**Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million**
Date: Mar-31-25 06:33PM 08:30AM
Source: (PR Newswire)
URL: https://www.prnewswire.com/news-releases/talphera-announces-agreement-with-the-fda-to-reduce-the-nephro-crrt-study-size-to-70-patients-from-166-and-a-private-placement-financing-priced-at-the-market-of-up-to-14-8-million-302415309.html

The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 patients, of which 6 patients are already enrolled

Talphera believes the NEPHRO CRRT study should be completed by the end of 2025

Existing investors, Nantahala Capital and Rosalind Advisors led the capital commitment priced at-the-market as defined by Nasdaq rules

$4.925 millionin gross

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TLPH_OUT_5 [2025-04-01 08:20:06 -0400] 903 Bytes | 271 tokens | Cum: 1314 tkns (16.43% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T07:03:18Z - Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights...
A2 - 2025-03-31T21:05:46Z - 12 Health Care Stocks Moving In Monday's After-Market Session - AquaBounty Techs (NASDAQ:AQB), Adver...
A3 - 2025-03-31T20:52:26Z - Talphera: Q4 Earnings Snapshot...
A4 - 2025-03-31T20:30:19Z - Talphera: Q4 Earnings Snapshot - WTOP News...
A5 - 2025-03-31T20:05:00Z - Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

TLPH_OUT_7 [2025-04-01 08:20:14 -0400] 1098 Bytes | 325 tokens | Cum: 1641 tkns (20.51% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights**Date: 2025-04-01Source: {'uri': 'ca.finance.yahoo.com', 'dataType': 'news', 'title': 'Yahoo! Finance'}URL: https://ca.finance.yahoo.com/news/talphera-inc-tlph-q4-2024-070318456.htmlPrivate Placement Investment: Agreement for up to $14.8 million in gross proceeds.

Cash Position: $8.9 million in cash as of December 31, 2024.

Operating Expenses: Combined R&D and SG&A expenses for Q4 2024 totaled $3 million, down from $4.6 million in Q4 2023.

Excluding Stock-Based Compensation: R&D and SG&A expenses were $2.8 million for Q4 2024, compared to $4.3 million for Q4 2023.

Projected Cash Operating Expenses for 2025: Expected to be in the range of $18 million to $19 million.

NEPHRO CRRT Study Size Reduction: FDA approved reduction from 166 patients to 70, maintaining 90% power for the primary en

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TLPH_OUT_9 [2025-04-01 08:20:14 -0400] 392 Bytes | 107 tokens | Cum: 1930 tkns (24.12% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-01-31T13:17:10Z - Why Sintx Technologies Shares Are Trading Higher By Over 39%; Here Are 20 Stocks Moving Premarket

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TLPH_OUT_11 [2025-04-01 08:20:18 -0400] 1100 Bytes | 300 tokens | Cum: 2232 tkns (27.90% of 8k)
==========================================================================

Showing B1 (chunk 1 of 2): B1:
**Why Sintx Technologies Shares Are Trading Higher By Over 39%; Here Are 20 Stocks Moving Premarket**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/24/01/36865230/why-sintx-technologies-shares-are-trading-higher-by-over-39-here-are-20-stocks-moving-premarketShares of Sintx Technologies, Inc. (NASDAQ: SINT) rose sharply in today’s pre-market trading after the company announced its subsidiary Technology Assessment & Transfer entered into a Cooperative Research and Development agreement with the U.S. Army Combat Capabilities Development Command Army Research Laboratory.
Sintx Technologies shares jumped 39.3% to $0.3393 in pre-market trading
Here are some other stocks moving in pre-market trading.
Gainers

Revelation Biosciences, Inc. (NASDAQ: REVB) gained 50.3% to $11.95 in pre-market trading after dipping around 39% on Tuesday.
Minim, Inc. (NASDAQ: MINM) sh

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TLPH_OUT_13 [2025-04-01 08:20:19 -0400] 1117 Bytes | 275 tokens | Cum: 2603 tkns (32.54% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K Item 7. Management s Discussion and Analysis of Fin Cond and Results of Oper

The following discussion and analysis should be read in conjunction with our audited financial statements and the related notes that appear elsewhere in this Annual Report on Form 10-...

S2 - 2025-03-31 8-K Item 2.02 Results of Oper and Fin Cond

On March 31, 2025, Talphera, Inc. (the Company) issued a press release announcing its financial results for the three and twelve months ended December 31, 2024 and providing a corporate update (the Release). A copy of the ...

S9 - 2024-11-13 10-Q ooking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the safe harbor created by that section. The forward-looking statements in this Form 10-Q are contained principally under Part I. Fin...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TLPH_OUT_15 [2025-04-01 08:20:19 -0400] 1098 Bytes | 245 tokens | Cum: 2850 tkns (35.62% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Management s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with our audited financial statements and the related notes that appear elsewhere in this Annual Report on Form 10-K.

The following discussion and analysis covers our financial condition and results of operations for the year ended December 31, 2024, including year-over-year comparisons versus the year ended December 31, 2023, as reported in our Annual Report on Form 10-K for the year ended December 31, 2023. This discussion and analysis as well as other parts of this Annual Report on Form 10-K contain forward-looking statements that involve risks and uncertainties, such as statements regarding our plans, objectives, expectations, intentions, and projections. Our actual results could differ materially from those discusse

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TLPH_OUT_17 [2025-04-01 08:20:25 -0400] 1098 Bytes | 258 tokens | Cum: 3110 tkns (38.88% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): d in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in Part I, Item 1A Risk Factors of this Annual Report on Form 10-K.

Overview

We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Our product development portfolio features Niyad (a regional anticoagulant for the dialysis circuit), LTX-608 (a nafamostat formulation for direct IV infusion) that we intend to develop for one or more of the following indications: disseminated intravascular coagulation, or DIC, acute respiratory distress syndrome, or ARDS, acute pancreatitis, or as an anti-viral treatment, and two ready-to-use pre-filled syringe product candidates (Fedsyra and phenylephrine).

Our strategy is focused on developing, obtaining

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TLPH_OUT_19 [2025-04-01 08:20:39 -0400] 5140 Bytes | 1554 tokens | Cum: 4783 tkns (59.79% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+----------------------+-------------------------+------------------------+
| Volume: 475,323 | Perf Month: -11.53% | Option/Short: Yes / Yes | Sales Y/Y TTM: -54.82% |
+--------------------+----------------------+-------------------------+------------------------+
| Avg Volume: 70.00K | Perf Quarter: -1.98% | Short Float: 0.62% | ROE: -111.91% |
+--------------------+----------------------+-------------------------+------------------------+
| Rel Volume: 7.41 | Index: - | Short Ratio: 1.49 | ROI: -96.80% |
+--------------------+----------------------+-------------------------+------------------------+
| RSI (14): 34.12 | Market Cap: 8.43M | Short Interest: 0.10M | Sales Surprise: - |
+--------------------+----------------------+-------------------------+------------------------+
| ATR (14): 0.06 | Shs Outstand: 17.03M | Beta: 0.19 | EPS Surprise: 57.58% |
+--------------------+----------------------+-------------------------+------------------------+
| SMA20: -14.26% | Shs Float: 16.67M | Sales Q/Q: -100.00% | P/E: - |
+--------------------+----------------------+-------------------------+------------------------+
| SMA50: -19.03% | Inst Own: 29.21% | Sales past 5Y: -2.84% | Earnings: Mar 31 AMC |
+--------------------+----------------------+-------------------------+------------------------+
| SMA200: -36.61% | Insider Own: 2.11% | Employees: - | |
+--------------------+----------------------+-------------------------+------------------------+
| Perf Week: -22.55% | Insider Trans: 4.52% | Debt/Eq: 0.68 | |
+--------------------+----------------------+-------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: TALPHERA, INC. (TLPH) by Angotti Vincent J. (CHIEF EXECUTIVE OFFICER) on 2025-02-14
- Common Stock: 10575 shares at $0.67 (D)

Inside Trans: TALPHERA, INC. (TLPH) by ASADORIAN RAFFI (Chief Financial Officer) on 2025-02-14
- Common Stock: 3245 shares at $0.67 (D)

Inside Trans: TALPHERA, INC. (TLPH) by Dasu Badri N (Chief Engineering Officer) on 2025-02-14
- Common Stock: 2644 shares at $0.67 (D)

Inside Trans: TALPHERA, INC. (TLPH) by Angotti Vincent J. (CHIEF EXECUTIVE OFFICER) on 2025-02-10
- Common Stock: 3515 shares at $0.6299 (D)
- Common Stock: 3517 shares at $0.62 (D)

Inside Trans: TALPHERA, INC. (TLPH) by ASADORIAN RAFFI (Chief Financial Officer) on 2025-02-10
- Common Stock: 1059 shares at $0.6299 (D)
- Common Stock: 1060 shares at $0.62 (D)

Inside Trans: TALPHERA, INC. (TLPH) by Dasu Badri N (Chief Engineering Officer) on 2025-02-10
- Common Stock: 879 shares at $0.6299 (D)
- Common stock: 880 shares at $0.62 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -3353000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.495
Average Volume: 47674.19
30-Day High: 0.6437
30-Day Low: 0.495

[Detailed Financials: Q3 2024]
- Total Assets: $21,014,000.0
- Total Liabilities: $11,373,000.0
- Total Equity: $9,641,000.0
- Current Assets: $12,195,000.0
- Current Liabilities: $2,762,000.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.13

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-2,306,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $24,856,000.0
- Total Liabilities: $12,126,000.0
- Total Equity: $12,730,000.0
- Current Assets: $16,037,000.0
- Current Liabilities: $3,274,000.0

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.15

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $1,301,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

TLPH_OUT_21 [2025-04-01 08:20:42 -0400] 676 Bytes | 167 tokens | Cum: 5235 tkns (65.44% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

TLPH_IN_23 [2025-04-01 08:20:43 -0400] 126 Bytes | 29 tokens | Cum: 5332 tkns (66.65% of 8k)
==========================================================================

====================================
[2025-04-01 08:20:43] # Analysis Completed
Elapsed Time: 42.92 seconds